Informations:
Erreur:
ID
14453
Description
Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00193245
Lien
https://clinicaltrials.gov/show/NCT00193245
Mots-clés
Versions (1)
- 15/04/2016 15/04/2016 -
Téléchargé le
15 avril 2016
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Lung Cancer NCT00193245
Eligibility Lung Cancer NCT00193245
- StudyEvent: Eligibility
Similar models
Eligibility Lung Cancer NCT00193245
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Inclusion criteria
Item
to be included in this study, you must meet the following criteria:
boolean
C1512693 (UMLS CUI [1])
Relapsed or progressive disease
Item
relapsed or progressive disease
boolean
C0277556 (UMLS CUI [1])
C1335499 (UMLS CUI [2])
C1335499 (UMLS CUI [2])
Lung cancer stage
Item
stage iiib (not candidate for combined modality) or iv
boolean
C0242379 (UMLS CUI [1,1])
C1515169 (UMLS CUI [1,2])
C1515169 (UMLS CUI [1,2])
Number of chemotherapy
Item
no more than one prior chemotherapy regimen
boolean
C0392920 (UMLS CUI [1,1])
C0237753 (UMLS CUI [1,2])
C0237753 (UMLS CUI [1,2])
No assistance in daily live
Item
able to perform activities of daily living without assistance
boolean
C0509063 (UMLS CUI [1,1])
C1518422 (UMLS CUI [1,2])
C1518422 (UMLS CUI [1,2])
Comorbidity site
Item
measurable disease outside of radiation port
boolean
C0009488 (UMLS CUI [1,1])
C1515974 (UMLS CUI [1,2])
C1515974 (UMLS CUI [1,2])
Bone marrow, liver and kidney function
Item
adequate bone marrow, liver and kidney function
boolean
C0005953 (UMLS CUI [1,1])
C0678852 (UMLS CUI [1,2])
C0232741 (UMLS CUI [2])
C0232804 (UMLS CUI [3])
C0678852 (UMLS CUI [1,2])
C0232741 (UMLS CUI [2])
C0232804 (UMLS CUI [3])
Cognitive function and informed consent
Item
must understand study and sign informed consent prior to enrollment
boolean
C0392335 (UMLS CUI [1])
C0021430 (UMLS CUI [2])
C0021430 (UMLS CUI [2])
Exclusion criteria
Item
you cannot participate in this study if any of the following apply to you:
boolean
C0680251 (UMLS CUI [1])
Topotecan or docetaxel
Item
prior treatment with topotecan or docetaxel
boolean
C0146224 (UMLS CUI [1])
C0246415 (UMLS CUI [2])
C0246415 (UMLS CUI [2])
Brain metastases
Item
uncontrolled brain metastases
boolean
C0220650 (UMLS CUI [1])
Peripheral neuropathy
Item
moderate peripheral neuropathy
boolean
C0031117 (UMLS CUI [1])
Additional inclusion/ exclusion criteria
Item
please note: there are additional inclusion/exclusion criteria. the study center will determine if you meet all of the criteria. if you do not qualify for the trial, study personnel will explain the reasons. if you do qualify, study personnel will explain the trial in detail and answer any questions you may have.
boolean
C1524062 (UMLS CUI [1,1])
C1512693 (UMLS CUI [1,2])
C1524062 (UMLS CUI [2,1])
C0680251 (UMLS CUI [2,2])
C1512693 (UMLS CUI [1,2])
C1524062 (UMLS CUI [2,1])
C0680251 (UMLS CUI [2,2])